Maria Feychting

Maria Feychting

Professor
E-postadress: maria.feychting@ki.se
Telefon: +46852487465
Besöksadress: Nobels väg 13, 17177 Stockholm
Postadress: C6 Institutet för miljömedicin, C6 Epidemiologi Feychting, 171 77 Stockholm
Del av:

Om mig

  • Jag är professor i epidemiologi vid Institutet för miljömedicin (IMM) och chef för Enheten för Epidemiologi. Forskningen vid enheten syftar till att öka kunskapen om påverkan från miljö- och livsstilsfaktorer samt andra riskfaktorer på risken för olika sjukdomar, särskilt cancer, hjärt-kärlsjukdomar och diabetes, och att öka förståelsen av den åldrande befolkningens hälsa och bestämningsfaktorer för livslängd.

Forskningsbeskrivning

  • Min forskning är framförallt inom cancerepidemiologi, med primärt fokus på hjärntumörer och barncancer, samt genetiska syndrom förknippade med ökad cancerrisk. Vi studerar riskfaktorer för cancerutveckling och faktorer som påverkar överlevnaden efter en cancerdiagnos. Vi studerar kemiska och fysikaliska yrkesmässiga exponeringar och sjukdomsrisk. Vi karakteriserar socioekonomiska skillnader i risk och överlevnad vid barncancer och hjärntumörer hos vuxna. I nordiska samarbeten har vi forskningsprogram fokuserade på socioekonomiska skillnader i barncancerrisk (SOFIA), samt sjuklighet och socioekonomiska konsekvenser i vuxenlivet efter barncancer (SALiCCS). Under senare år har denna forskning utvidgats till att omfatta genetiska cancersyndrom, som exempelvis neurofibromatos och tuberös skleros. I många av våra studier använder vi de unika befolknings- och hälsodataregistren som finns i Sverige och de nordiska länderna, men vi samlar även in data för forskning genom enkäter och intervjuer.

    Jag har forskat om potentiella hälsoeffekter av icke-joniserande strålning sedan slutet av 1980-talet och är för närvarande projektledare för den svenska delen av COSMOS-studien – en internationell prospektiv kohortstudie av mobiltelefonanvändare. Jag har lett den svenska komponenten i flera internationella fall-kontrollstudier, såsom Interphone-studien av hjärntumörer hos vuxna, och Cefalo-studien av hjärntumörer bland barn.

    Under det senaste decenniet har min forskning finansierats av Vetenskapsrådet, Forskningsrådet för hälsa, arbetsliv och välfärd, Cancerfonden, Barncancerfonden, Nordforsk och Strålsäkerhetsmyndigheten.

    Jag är mycket engagerad i hälsoriskbedömningsarbete, vilket är en del av Institutet för miljömedicins särskilda uppdrag. Jag har varit vetenskaplig expert i flera nationella och internationella offentliga expertgrupper angående potentiella hälsoeffekter av exponering för icke-joniserande strålning, för närvarande för Världshälsoorganisationen (WHO). Jag var vice ordförande (2012-2020) i International Commission on Non-Ionizing Radiation Protection (ICNIRP), ett oberoende organ som rekommenderar vetenskapligt baserade riktlinjer för skydd mot skadliga nivåer av icke-joniserande strålning, vilka används av en majoritet av de länder som använder referensvärden för denna typ av exponering, inklusive Sverige.

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Swedish Research Council
    1 January 2024 - 31 December 2026
    The association between weight, and cardiovascular disease and mortality is well established, however, the causal effect of weight-loss in midlife on these outcomes is less clear. Bariatric surgery results in substantial weight-loss and is an ideal candidate to study the causal effects of weight-loss. We propose a project that willcausal inference and machine learning methods to answer two important questions: 2) Is bariatric surgery effective for reducing cardiovascular disease and mortality, and if so, for who? 3) Which type of bariatric surgery (gastric bypass or sleeve gastrectomy) is most effective, and for who?We will use data from various Swedish registers to identify individuals with obesity who are eligible for bariatric surgery. We will then compare cardiovascular and mortality outcomes among those undergoing different types of bariatric surgery with those receiving non-surgical obesity management using causal inference methods. We will use causal forests and expert knowledge to estimate indiviual treatment effects, and identify the groups of patients who benefit the most from these surgeries.This 3-year project will be undertaken by the CAUSALab, at the Unit of Epidemiology, Karolinska Institutet. The team of co-applicants, have extensive experience in using observational data to obtain causal inferences, particularly in the field of cardiovascular disease. A postdoctoral researcher will be hired to work full-time on this project.
  • Swedish Research Council
    1 January 2023 - 31 December 2025
    This proposal aims to utilize the pandemic as a “natural experiment”, by studying childhood cancer incidence before, during and after the pandemic in Sweden, Denmark, and Finland. The pandemic has provided a unique opportunity to test the hypothesis of an infectious disease etiology for acute lymphoblastic leukemia, enhanced by the different pandemic strategies in the Nordic countries. We also aim to study the impact of the COVID-19 pandemic on childhood cancer patients, both regarding susceptibility to COVID-19 in long-term childhood cancer survivors, and, for those diagnosed with childhood cancer during the pandemic, whether the path through primary care to cancer diagnosis and short-term survival has changed compared to the period prior to the pandemic. An important aspect of this project is that we will study if the social inequalities in number of contacts with healthcare and childhood cancer survival have worsened during the pandemic.We will utilize the unique infrastructure for register-based research in the Nordic countries: for incidence trends and health care pattern around the pandemic, new data will be collected from national health data registers and regional primary care. For COVID-19 risk in long-term survivors the unique Nordic cohort of childhood cancer survivors, SALiCCS, will be utilized, including 20 000 survivors, their siblings, and population controls.The project will provide new knowledge on childhood cancer etiology and childhood cancer late effects.
  • Swedish Research Council
    1 January 2022 - 31 December 2025
    Randomized trials do not estimate treatment effects in individuals that were eligible but did not enroll in the trial. However, guidelines established as a result of the trials apply to these populations in clinical practice. On average, around 40% of eligible individuals do not enroll in trials. A treatment that shows no benefit in trial participants may be effective in a subpopulation not likely to enroll, such as older individuals. Differences in effectiveness must be quantified to guide policy decisions. Extending randomized trial results to the treatment eligible population is often handled using real-world data alone, which are prone to bias.This project will propose a novel framework that uses transportability and benchmarking methods to simultaneously utilize data from the TASTE and VALIDATE randomized trials and real-world data from the SWEDEHEART registry to robustly fill the knowledge gaps left by the trials. Specifically, we will estimate the effect of thrombus aspiration and two anticoagulant medications after myocardial infarction in the whole trial-eligible population of Sweden
    test the reliability of studies that use real-world data alone to estimate treatment effects
    and create tutorials, teaching materials, and open-source code to facilitate the uptake of these methodologies. Our research will improve public health decisions in Sweden and serve as a model in the extension of findings from randomized trials to the population eligible for treatment.
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2022 - 31 December 2024
  • Barncancerfonden
    1 January 2022 - 31 December 2022
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2021 - 31 December 2023
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2020 - 31 December 2022
  • Swedish Research Council
    1 January 2018 - 31 December 2021
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2018 - 31 December 2020
  • Swedish Research Council
    1 January 2018 - 31 December 2020
  • Brain Tumor, Neurofibromatosis and Other Genetic Cancer Symptoms - A Deepening of the Knowledge of Risk Factors for Nervous System Tumors
    Swedish Cancer Society
    1 January 2017
    Nervous system tumors affect over 1000 people annually, and the prognosis is often poor. Known risk factors are several genetic cancers and ionizing radiation. Factors associated with pregnancy and childbirth appear to be important for the onset of brain tumor in children, as well as childhood cancer in general. We also saw similar relationships for tumors in the nervous system in adults. About 50% of the cancer syndrome, which is characterized by a high incidence of nerve system tumors, has no known family history. de novo case. There are studies of single cases but very few epidemiological studies of these, and indications that the father's age is important. The purpose of the research program is to further deepen the knowledge of the causes of tumors in the nervous system. We want to investigate whether the risk increases observed in relation to factors during pregnancy and childbirth can be explained by cancer syndrome. To further deepen our knowledge, we also want to identify factors that affect the risk of suffering from any of these cancer syndromes among people who have no family history. We also intend to continue to follow the incidence trend for brain tumors, and to make descriptive analyzes of the prevalence of the genetic cancer syndromes in Sweden, which has never been done at present. We hope to be able to provide in-depth knowledge of the causes of tumors in the nervous system, and of de novo genetic syndromes that are associated with increased incidence of such tumors. There is as yet no systematic description of the incidence of these cancer syndromes in Sweden, and recently a Finnish study reported a higher incidence than previously known. In Sweden, we have a unique opportunity to carry out this type of study and can contribute important information in the area, using our unique health data registers.
  • Brain Tumor, Neurofibromatosis and Other Genetic Cancer Symptoms - A Deepening of the Knowledge of Risk Factors for Nervous System Tumors
    Swedish Cancer Society
    1 January 2016
    Nervous system tumors affect over 1000 people annually, and the prognosis is often poor. Known risk factors are several genetic cancers and ionizing radiation. Factors associated with pregnancy and childbirth appear to be important for the onset of brain tumor in children, as well as childhood cancer in general. We also saw similar relationships for tumors in the nervous system in adults. About 50% of the cancer syndrome, which is characterized by a high incidence of nerve system tumors, has no known family history. de novo case. There are studies of single cases but very few epidemiological studies of these, and indications that the father's age is important. The purpose of the research program is to further deepen the knowledge of the causes of tumors in the nervous system. We want to investigate whether the risk increases observed in relation to factors during pregnancy and childbirth can be explained by cancer syndrome. To further deepen our knowledge, we also want to identify factors that affect the risk of suffering from any of these cancer syndromes among people who have no family history. We also intend to continue to follow the incidence trend for brain tumors, and to make descriptive analyzes of the prevalence of the genetic cancer syndromes in Sweden, which has never been done at present. We hope to be able to provide in-depth knowledge of the causes of tumors in the nervous system, and of de novo genetic syndromes that are associated with increased incidence of such tumors. There is as yet no systematic description of the incidence of these cancer syndromes in Sweden, and recently a Finnish study reported a higher incidence than previously known. In Sweden, we have a unique opportunity to carry out this type of study and can contribute important information in the area, using our unique health data registers.
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2016 - 31 December 2018
  • Swedish Research Council for Health Working Life and Welfare
    1 December 2015 - 30 September 2016
  • Brain Tumor, Neurofibromatosis and Other Genetic Cancer Symptoms - A Deepening of the Knowledge of Risk Factors for Nervous System Tumors
    Swedish Cancer Society
    1 January 2015
    Nervous system tumors affect over 1000 people annually, and the prognosis is often poor. Known risk factors are several genetic cancers and ionizing radiation. Factors associated with pregnancy and childbirth appear to be important for the onset of brain tumor in children, as well as childhood cancer in general. We also saw similar relationships for tumors in the nervous system in adults. About 50% of the cancer syndrome, which is characterized by a high incidence of nerve system tumors, has no known family history. de novo case. There are studies of single cases but very few epidemiological studies of these, and indications that the father's age is important. The purpose of the research program is to further deepen the knowledge of the causes of tumors in the nervous system. We want to investigate whether the risk increases observed in relation to factors during pregnancy and childbirth can be explained by cancer syndrome. To further deepen our knowledge, we also want to identify factors that affect the risk of suffering from any of these cancer syndromes among people who have no family history. We also intend to continue to follow the incidence trend for brain tumors, and to make descriptive analyzes of the prevalence of the genetic cancer syndromes in Sweden, which has never been done at present. We hope to be able to provide in-depth knowledge of the causes of tumors in the nervous system, and of de novo genetic syndromes that are associated with increased incidence of such tumors. There is as yet no systematic description of the incidence of these cancer syndromes in Sweden, and recently a Finnish study reported a higher incidence than previously known. In Sweden, we have a unique opportunity to carry out this type of study and can contribute important information in the area, using our unique health data registers.
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2015 - 31 December 2017
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2014 - 31 December 2016
  • Swedish Research Council
    1 January 2014 - 31 December 2018
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2011 - 31 December 2013
  • Swedish Research Council
    1 January 2011 - 31 December 2013
  • Visa fler

Anställningar

  • Professor, Institutet för miljömedicin, Karolinska Institutet, 2005-

Examina och utbildning

  • Docent, Epidemiologi, Karolinska Institutet, 2001

Nyheter från KI

Kalenderhändelser från KI